Nimotuzumab Combined With Concurrent Curative Radiotherapy and S-1 in 75 Years and Older Patients With Stage II-IVB Esophageal Squamous Cell Carcinoma: A Phase II Study.
Xiaojie Xia, Jingze Yan, Lu Xu et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase II study evaluated the efficacy and safety of nimotuzumab combined with concurrent radiotherapy and S-1 in patients aged 75 and older with stage II-IVB esophageal squamous cell carcinoma. The study included 56 patients, revealing a median progression-free survival of 25.3 months and a median overall survival of 28.2 months, indicating promising outcomes for this demographic.
Key findings
- Median progression-free survival was 25.3 months (95% CI, 16.5-34.1).
- Median overall survival was 28.2 months (95% CI, 24.1-32.3).
- Eleven patients achieved complete response, while 39 had partial response.
- 85.7% of adverse events were grade 1-2.
Why it matters
The study highlights a potential treatment strategy for older patients with esophageal cancer, a group often underrepresented in clinical trials. Understanding the efficacy and safety of this combination therapy can help clinicians make informed decisions for managing this vulnerable population.